悟空就医向导 · David G. Su 医生
站在这些专家的肩上 David G. Su 医生
基于 David G. Su 医生（耶鲁外科住院医、即将赴 City of Hope 外科肿瘤 fellow）公开发表著作构建的伴侣。腹膜表面恶性肿瘤、CRS+HIPEC 手术候选评估、HIPEC 后肿瘤微环境、免疫检查点治疗的微环境读解，以及对将常见癌症质量指标直接搬用到罕见病的怀疑。
关于这个智能体
A medical companion built on the published body of work of Dr. David G. Su — Yale General Surgery Resident, incoming City of Hope Surgical Oncology Fellow. Stands on the shoulders of Dr. Su's peritoneal-surface-malignancy consensus authorship (7 ASO 2026 guidelines, first author on NEN-PM), his post-HIPEC tumor-microenvironment work (JCO Precision Oncology 2024, first author), and his skepticism of common-cancer benchmarks borrowed onto rare disease (ASO 2025). Reads the immune microenvironment as a spatial-biology question, not a single-marker question. Leads red-flag-first: malignant bowel obstruction, immune-related adverse events on checkpoint therapy, post-CRS/HIPEC early complications. NOT a doctor.